(Q24813259)

4 July 2017

title

Efficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter study (English)

1 reference

multicenter clinical trial

4 July 2017

main subject

0 references

0 references

Charles M Fogarty

1

Charles M

Fogarty

1 reference

4 July 2017

Tushar C Patel

series ordinal

2

author given names

Tushar C

author last names

Patel

1 reference

4 July 2017

Lala M Dunbar

series ordinal

3

author given names

Lala M

author last names

Dunbar

1 reference

4 July 2017

Bruno P Leroy

series ordinal

4

author given names

Bruno P

author last names

Leroy

1 reference

4 July 2017

language of work or name

English

0 references

publication date

31 May 2005

1 reference

4 July 2017

published in

BMC Infectious Diseases

1 reference

4 July 2017

volume

5

1 reference

4 July 2017

issue

1

0 references

page(s)

43

1 reference

Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention

4 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1177948

Efficacy and tolerability of once-daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1177948

Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647).

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1177948

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1177948

In vitro activities of the novel ketolide telithromycin (HMR 3647) against erythromycin-resistant Streptococcus species

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1177948

The in vitro activity of ABT773, a new ketolide antimicrobial agent

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1177948

Antimicrobial resistance in Streptococcus pneumoniae: implications for patients with community-acquired pneumonia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1177948

Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1177948

In vitro pharmacodynamics of the new ketolides HMR 3004 and HMR 3647 (Telithromycin) against Chlamydia pneumoniae

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1177948

In vitro activity of telithromycin (HMR3647), a new ketolide, against clinical isolates of Mycoplasma pneumoniae in Japan

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1177948

The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1177948

In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1177948

In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1177948

Activity of HMR 3647 compared to those of five agents against Haemophilus influenzae and moraxella catarrhalis by MIC determination and time-kill assay

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1177948

Susceptibilities of Legionella spp. to newer antimicrobials in vitro

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1177948

In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1177948

Antibacterial effect of telithromycin (HMR 3647) and comparative antibiotics against intracellular Legionella pneumophila

28 September 2017

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-5-43

Comparative in vitro activity of telithromycin (HMR 3647), three macrolides, amoxycillin, cefdinir and levofloxacin against gram-positive clinical isolates in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-5-43

Lung concentrations of telithromycin after oral dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-5-43

Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-5-43

Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-5-43

Bacteremic and nonbacteremic pneumococcal pneumonia. A prospective study

21 January 2018

1 reference

12 December 2020

Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America

1 reference

12 December 2020

Ketolides lack inducibility properties of MLS(B) resistance phenotype

1 reference

12 December 2020

Community-acquired pneumonia

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2334-5-43

1 reference

Dimensions Publication ID

4 July 2017

1023509274

0 references

PMC publication ID

1177948

0 references

1 reference